Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/105787LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47
WO 27.05.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/131181 Applicant SHENZHEN ENDURING BIOTECH, LTD. Inventor WEN, Yu
Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.
2.WO/2022/100696MULTI-SPECIFIC BIOCONJUGATE LINKER AND SYNTHETIC METHOD THEREFOR
WO 19.05.2022
Int.Class C07D 257/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
257Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
08Six-membered rings
Appl.No PCT/CN2021/130337 Applicant PEKING UNIVERSITY Inventor CHEN, Peng
Disclosed in the present application are a multi-specific bioconjugate linker and a synthetic method therefor, and specifically, a compound or a tautomer, a mesomer, a racemate, an enantiomer, or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. Also disclosed in the present application are a preparation method for the compound and use in tumor treatment.
3.WO/2022/098822CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS
WO 12.05.2022
Int.Class A61P 19/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
Appl.No PCT/US2021/057986 Applicant ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Inventor HOFFMAN, Ronald
Provided herein are compositions comprising CXCR1/CXCR2 inhibitors as well as methods of using the CXCR1/CXCR2 inhibitors disclosed herein. In embodiments, provided are methods of treating myelofibrosis, methods of decreasing bone marrow fibrosis, methods of reducing the interaction of IL-8 to CXCR1 and/or CXCR2, and methods of reducing the activity or and/or signaling through CXCR1 and/or CXCR by administering to a subject in need thereof an effective amount of a CXCR1/CXCR2 inhibitor disclosed herein.
4.WO/2022/089382EXOSOMES CONTAINING MIRNAS TARGETING HER2 SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS
WO 05.05.2022
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/CN2021/126208 Applicant IMMVIRA CO., LIMITED Inventor CHEN, Xiaoqing
Disclosed is an engineered exosome comprising a miRNA targeting human epidermal growth factor receptor 2 (HER2) synthesis and a ligand displayed on a membrane of the exosome for specific binding to a HER2 protein expressed on a cancer cell.
5.WO/2022/093671GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS
WO 05.05.2022
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/US2021/056413 Applicant PARTNER THERAPEUTICS, INC. Inventor FELDHAUS, Michael
The present invention is based on the discovery that amino acid substitutions in the sequence of sargramostim yield a product with simplified manufacturability.
6.WO/2022/079032METHODS FOR DETECTING A TARGET IN A SAMPLE USING MUTATED NANOBODIES
WO 21.04.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/EP2021/078184 Applicant UNIVERSITE DE LILLE Inventor SZUNERITS, Sabine
The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.
7.20220118089METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS WITH ECM-AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
US 21.04.2022
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 17310802 Applicant The University of Chicago Inventor Jeffrey A. HUBBELL

The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.

8.2022062061FLT3及びCD3に対する抗体構築物
JP 19.04.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 2022004318 Applicant アムゲン リサーチ (ミュンヘン) ゲーエムベーハー Inventor ラウム トビアス
【課題】急性骨髄性白血病(AML)の治療のためのモノクローナル抗体を含む、二重特異性抗体構築物を提供する。
【解決手段】標的細胞の表面に存在するヒトFLT3に結合する第1の結合ドメインと、T細胞の表面に存在するヒトCD3に結合する第2の結合ドメインと、を含む二重特異性抗体構築物であって、前記第1の結合ドメインが、特定の配列に示される領域内に含まれるFLT3のエピトープに結合する、前記二重特異性抗体構築物、該抗体構築物をコードするポリヌクレオチド、該ポリヌクレオチドを含むベクター、該ポリヌクレオチドまたはベクターで形質転換されたかまたはそれを遺伝子導入された宿主細胞を提供する。さらに、本開示は、本開示の抗体構築物の産生のための方法、当該抗体構築物の医学的使用、及び当該抗体構築物を含むキットを提供する。
【選択図】なし
9.114369169用于预防或治疗病毒和其它微生物感染的组合物
CN 19.04.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 202111210758.4 Applicant 优瑞科生物技术公司 Inventor 刘诚
本申请涉及用于预防或治疗病毒和其它微生物感染的组合物。在一些实施例中,本申请提供了包含特异性地结合至通过黏膜感染的病原体的靶结合部分和带正电荷的黏膜粘附肽片段的嵌合蛋白。还提供了特异性地结合至SARS‑CoV‑2的刺突蛋白的S1亚基的抗体及其构建体。包含本文所述的嵌合蛋白、抗体或构建体的组合物可用于预防或治疗个体中的微生物感染,如冠状病毒感染。
10.WO/2022/076378METHODS FOR DETECTING ANTIBODIES
WO 14.04.2022
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Appl.No PCT/US2021/053525 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor ZHOU, Xianjin
Provided herein are methods of preparing a detectable antibody-antibody binding agent aggregate, the method comprising: (a) contacting a biological sample with an antibody binding agent, wherein the antibody binding agent comprises an antibody binding antigen and a detectable label, wherein the antibody binding agent binds an antibody in the biological sample; (b) adding an aggregating agent to the biological sample, wherein the aggregating agent binds to the antibody and forms an antibody-antibody binding agent aggregate; and (c) detecting a signal from the detectable label of the antibody binding agent associated with the antibody-antibody binding agent aggregate, thereby preparing a detectable antibody-antibody binding agent aggregate.